Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 7/20 | 0.43 |
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | CTSB | P07858 | 6/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874791 | 0.87 | ATM (0.53) | CTSLSYKCTSSCTSKCTSB | |
| SCHEMBL21609299 | 0.87 | ATM (0.53) | CTSLSYKCTSSCTSKCTSB | |
| SCHEMBL23721718 | 0.86 | CTSS (0.58) | CTSLSYKCTSSCTSKCTSB | |
| SCHEMBL29847901 | 0.86 | CTSS (0.58) | CTSLSYKCTSSCTSKCTSB | |
| SCHEMBL1185574 | 0.84 | CTSL (0.59) | CTSLKDM4ESYKCTSSCTSK | |
| SCHEMBL1519856 | 0.81 | CTSL (0.62) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL742227 | 0.81 | CTSL (0.62) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL742226 | 0.81 | CTSL (0.62) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL21610487 | 0.79 | PTGFR (0.47) | CTSLKDM4ESYKCTSSCTSK | |
| SCHEMBL21609291 | 0.79 | PTGFR (0.47) | CTSLKDM4ESYKCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4316504-A2 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3810633-B1 | COMPOUNDS | SPERO THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3810633-B1 | COMPOUNDS | SPERO THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11459357-B2 | Polymyxin compounds | SPERO THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| CN-112789287-A | Compound (I) | 斯佩罗治疗公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3810633-A1 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | CTSL 697/4885KDM4E 981/4885SYK 107/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | CTSL 2064/4885KDM4E 952/4885SYK 90/4885 |
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | CTSL 725/4885KDM4E 1268/4885SYK 910/4885 |
| US-11459357-B2 | Polymyxin compounds | MRPL37, MRPS18A, PNISR | CTSL 1033/4885KDM4E 1561/4885SYK 817/4885 |
| US-20210246169-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPS35 | CTSL 941/4885KDM4E 1521/4885SYK 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.